Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06376240
NA

The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes

Sponsor: Maastricht University Medical Center

View on ClinicalTrials.gov

Summary

Patients with type 2 diabetes have an increased risk of developing vascular complications. Microvascular dysfunction might be caused by the increased production of methylglyoxal under hyperglycaemic conditions. Methylglyoxal is a by-product of glycolysis and forms advanced glycation endproducts (AGEs) on proteins and DNA, thereby disrupting their function. Preventing methylglyoxal accumulation and AGEs formation may offer a therapeutic option for treating microvascular complications in diabetics. Pyridoxamine is a vitamin B6 vitamer that scavenges methylglyoxal and thereby inhibits the formation of AGEs. In this study, the researchers investigate whether pyridoxamine supplementation in type 2 diabetes improves microvascular function in the eye, kidney and skin, and reduces markers of endothelial dysfunction and glycation.

Official title: The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes: a Double-blind Randomized Placebo-controlled Crossover Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-03-21

Completion Date

2026-03-13

Last Updated

2026-04-27

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Pyridoxamine 300mg per day

oral supplement

OTHER

Placebo 300mg placebo per day

oral supplement

Locations (1)

Academic Hospital Maastricht

Maastricht, Netherlands